The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer (Q37599158)

21 August 2017

1 reference

title

The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer (English)

1 reference

21 August 2017

0 references

1 reference

Jörg Ellinger

1

1 reference

21 August 2017

Stefan C Müller

2

1 reference

21 August 2017

Thomas C Stadler

3

1 reference

21 August 2017

Andreas Jung

4

1 reference

21 August 2017

Alexander von Ruecker

5

1 reference

21 August 2017

Patrick J Bastian

6

1 reference

21 August 2017

17 September 2009

1 reference

21 August 2017

1 reference

21 August 2017

29

1 reference

21 August 2017

2

1 reference

21 August 2017

124-129

1 reference

21 August 2017

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Mortality results from a randomized prostate-cancer screening trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Screening and prostate-cancer mortality in a randomized European study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Circulating nucleosomes and response to chemotherapy: an in vitro, in vivo and clinical study on cervical cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Cell-free circulating DNA: diagnostic value in patients with testicular germ cell cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Apoptotic DNA fragments in serum of patients with muscle invasive bladder cancer: a prognostic entity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Neoplastic characteristics of the DNA found in the plasma of cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Cell-free DNA: measurement in various carcinomas and establishment of normal reference range

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Prediction of breast tumor progression by integrity of free circulating DNA in serum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Identification of loss of heterozygosity on circulating free DNA in peripheral blood of prostate cancer patients: potential and technical improvements.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Rapid clearance of fetal DNA from maternal plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Higher amount of free circulating DNA in serum than in plasma is not mainly caused by contaminated extraneous DNA during separation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Effects of preanalytical factors on the molecular size of cell-free DNA in blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Role of cell-free plasma DNA as a diagnostic marker for prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Cell-free DNA and RNA in plasma as a new molecular marker for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Prospective Study of Quantitation of Plasma DNA Levels in the Diagnosis of Malignant versus Benign Prostate Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Deoxyribonuclease activity and circulating DNA concentration in blood plasma of patients with prostate tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

DNA integrity assay: a plasma-based screening tool for the detection of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Comparison of genetic alterations detected in circulating microsatellite DNA in blood plasma samples of patients with prostate cancer and benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Multimarker circulating DNA assay for assessing blood of prostate cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Methylation-specific sequencing of GSTP1 gene promoter in circulating/extracellular DNA from blood and urine of healthy donors and prostate cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Hypermethylation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

CpG island hypermethylation of cell-free circulating serum DNA in patients with testicular cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

Mitochondrial DNA in serum of patients with prostate cancer: a predictor of biochemical recurrence after prostatectomy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

The role of cell-free DNA size distribution in the management of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.05.010

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.UROLONC.2009.05.010

1 reference

21 August 2017

1 reference